

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 725 078 A1

B 1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
07.08.1996 Bulletin 1996/32

(51) Int Cl.⁶: C07K 14/47, A61K 38/17

(21) Application number: 96300612.7

(22) Date of filing: 29.01.1996

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
SE

(30) Priority: 31.01.1995 US 381048
06.02.1995 US 383638

(71) Applicant: ELI LILLY AND COMPANY
Indianapolis, Indiana 46285 (US)

(72) Inventors:
• Basinsky, Margret B.
Indianapolis, Indiana 46219 (US)
• Dimarchi, Richard D.
Carmel, Indiana 46033 (US)

• Heath Jr., William F.
Fishers, Indiana 46038 (US)
• Schoner, Brigitte E.
Monrovia, Indiana 46157 (US)

(74) Representative: Tapping, Kenneth George et al
Lilly Industries Limited
European Patent Operations
Erl Wood Manor
Windlesham Surrey GU20 6PH (GB)

Remarks:

The applicant has subsequently filed a sequence
listing and declared, that it includes no new matter.

(54) Anti-obesity proteins

(57) The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue.
Peptides of invention are represented by mentioned DNA string or analogs thereof:

```

      5              10              15
Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys Thr Leu Ile Lys Thr
      20              25              30
Ile Val Thr Arg Ile Asp Asp Ile Ser His Thr Gln Ser Val Ser Ser
      35              40              45
Lys Gln Lys Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro Ile
      50              55              60
Leu Thr Leu Ser Lys Met Asp Gln Thr Leu Ala Val Tyr Gln Gln Ile
      65              70              75              80
Leu Thr Ser Met Pro Ser Arg Asn Val Ile Gln Ile Ser Asn Asp Leu
      85              90              95
Glu Asn Leu Arg Asp Leu Leu His Val Leu Ala Phe Ser Lys Ser Cys
      100             105             110
His Leu Pro Trp Ala Ser Gly Leu Glu Thr Leu Asp Ser Leu Gly Gly
      115             120             125
Val Leu Glu Ala Ser Gly Tyr Ser Thr Glu Val Val Ala Leu Ser Arg
      130             135             140
Leu Gln Gly Ser Leu Gln Asp Met Leu Trp Gln Leu Asp Leu Ser Pro
      145
Gly Cys

```

Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

EP 0 725 078 A1

BEST AVAILABLE COPY